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Background:  The common characteristics of metabolic syndrome (MetS) and Cushing’s syndrome suggest that excess cortisol 
may be involved in the pathogenesis of MetS. Salivary cortisol measurements are simple and can be surrogates for plasma free 
cortisol, which is the most biologically active form. We evaluated the association between levels of midnight salivary cortisol and 
MetS in Korean adults. 
Methods:  A total of 46 subjects, aged 20 to 70 years, who visited the Health Care Center at Konkuk University Hospital from 
August 2008 to August 2009 were enrolled. We compared the levels of midnight salivary cortisol in subjects with MetS with those 
in subjects without MetS. We analyzed the associations between midnight salivary cortisol levels and components of MetS. 
Results:  Midnight salivary cortisol levels were higher in the MetS group (70±42.4 ng/dL, n=12) than that in the group without 
MetS (48.1±36.8 ng/dL, n=34) (P=0.001). Positive correlations were observed between midnight salivary cortisol levels and waist 
circumference, fasting blood glucose, and homeostasis model assessment of insulin resistance. The risk for MetS was significant-
ly higher in subjects with midnight salivary cortisol levels ≥100 ng/dL than in those with levels <50 ng/dL (odds ratio, 5.9; 95% 
confidence interval, 2.35 to 36.4). 
Conclusion:  The results showed a positive correlation between midnight salivary cortisol levels and MetS, suggesting that hy-
percortisolism may be related to MetS. 
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INTRODUCTION
Metabolic syndrome (MetS) is characterized by abdominal 
obesity, dyslipidemia, hyperglycemia, and hypertension, and 
was firmly established as a clinically important syndrome by 
Reaven in 1998 [1,2]. MetS is associated with the future devel-
opment of type 2 diabetes and coronary heart disease [3].
  The prevalence of MetS has increased rapidly worldwide, 
and has become an important public health challenge [4]. The 
prevalence of MetS is 30% to 33.7% in Korean adults by the 
International Diabetes Federation (IDF) criteria and it has in-
creased as central obesity has increased [5,6]. However, the 
pathogenesis of MetS remains controversial. 
  MetS and Cushing’s syndrome are both characterized by a 
cluster of common abnormalities such as abdominal obesity, 
hyperglycemia, hypertension, reduced high-density lipopro-
tein cholesterol (HDL-C), and elevated triglycerides. The com-
mon characteristics of MetS and Cushing’s syndrome suggest 
that the production of excess cortisol may be involved in the 
pathogenesis of MetS. Evidence supporting this hypothesis in-
clude the association of increased stress-related cortisol secre-
tion with features of MetS, and higher circulating cortisol con-
centrations and increased urinary cortisol metabolite secretion 
in men with MetS [7,8]. 
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  It has been convincingly demonstrated in adults and chil-
dren that an elevated midnight salivary cortisol level is an ex-
cellent surrogate for increased midnight serum cortisol, which 
means disruption of diurnal variation in the diagnosis of Cush-
ing’s syndrome [9-13]. In addition, measuring salivary cortisol 
has several advantages. It reflects the unbound fraction of cir-
culating cortisol, and, thus, is not affected by any alterations in 
cortisol-binding globulin and is not influenced by salivary flow 
rate [14]. Furthermore, salivary cortisol levels provide a more 
sensitive approach to assess the subtle activation of the hypo-
thalamus-pituitary-adrenal (HPA) axis than urine-free corti-
costeroids [14,15]. 
  This study was designed to evaluate the potential contribu-
tion of hypercortisolism to the development of MetS in Kore-
an adults using midnight salivary cortisol as a marker for en-
dogenous cortisol status. 
METHODS
Subjects
A total of 46 subjects aged 20 to 70 years, who visited the Health 
Care Center at Konkuk University Hospital for a regular health 
check-up from August 2008 to August 2009 were enrolled. In-
formed consent was obtained from all subjects, and the proto-
cols were approved by the Konkuk University Hospital Institu-
tional Review Board.
  Exclusion criteria were as follows: 1) type 1 diabetes; 2) type 
2 diabetes with a glycated hemoglobin >10%; 3) Cushing’s 
syndrome (Cushingoid appearance or midnight salivary corti-
sol >145 ng/dL) or pseudo-Cushing’s syndrome (alcoholic or 
depressive disorder); 4) adrenal insufficiency; 5) serum creati-
nine level >2 mg/dL; 6) aspartate aminotransferasse and ala-
nine aminotransferase levels more than three times the upper 
normal limit; 7) receiving steroid medications (including topi-
cal agents); 8) malignant tumor; and 9) poor oral hygiene.
Measurements 
Systolic and diastolic blood pressures were measured on the 
left upper arm after 5 minutes of rest in the sitting position us-
ing an automatic blood pressure monitor (HEM-907-E; OM-
ROM, Tokyo, Japan). Abdominal circumference was measured 
in the standing position at the midway between the lower cos-
tal margin and the iliac crest. Blood glucose, total cholesterol, 
triglycerides, HDL-C, low density lipoprotein cholesterol, in-
sulin, and other biochemical tests were performed after a 12-
hour fast. Saliva samples were obtained between 23:00 and 
24:00; a cotton stick was placed in the mouth for 2 to 3 minutes 
and then replaced into the saliva-collecting device (Salicap; 
IBL, Hamburg, Germany). Because food ingestion and physical 
stress can increase circulating cortisol levels, subjects were re-
quested to abstain from physical activity and food from 21:00 
until they were sampled. Samples were stored at -20°C until as-
say and then centrifuged at 500 rpm for 5 minutes. Salivary 
cortisol concentrations were determined using a competitive 
enzyme immunoassay kit (Salimetrics Inc., State College, PA, 
USA). The detection limit range of the kit was 3 to 3,000 ng/dL. 
The average intra-assay coefficient of variation was 8.2% and 
the inter-assay coefficient of variation was 12.8%.
  Insulin resistance was calculated from fasting insulin and 
glucose values using the homeostasis model assessment-insu-
lin resistance (HOMA-IR). The formula was as follows:
     HOMA-IR=fasting insulin (U/mL)×fasting blood glucose 
(mmol/L)/22.5
Definition of MetS
MetS was diagnosed based on the criteria of the IDF. Subjects 
were identified as having MetS if they had abdominal obesity 
(waist circumference ≥90 cm in men, ≥80 cm in women) plus 
two or more of the following criteria: 
1) Triglycerides: ≥150 mg/dL 
2) HDL-C: <40 mg/dL in men, <50 mg/dL in women
3) Blood pressure: systolic blood pressure ≥130 mm Hg   
or diastolic blood pressure ≥85 mm Hg or treatment for 
previously diagnosed hypertension
4) Fasting blood glucose: ≥100 mg/dL or previously diag-
nosed type 2 diabetes 
Statistical analysis
The statistical analysis was performed with SPSS version 17.0 
(SPSS Inc., Chicago, IL, USA), and data are presented as medi-
ans (interquartile range). The Mann-Whitney U test and chi-
squared test were used to assess differences in clinical charac-
teristics between those with and without MetS. Partial correla-
tion was used to assess the association between midnight sali-
vary cortisol and abdominal circumference, blood pressure, 
triglycerides, HDL-C, fasting blood glucose, HOMA-IR, and 
high sensitivity C-reactive protein. A logistic regression analy-
sis was carried out to test the association between midnight 
salivary cortisol and MetS. Statistical significance was defined 
at P<0.05.247
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RESULTS
General subject characteristics 
Table 1 shows a comparison of the characteristics of those with 
and without MetS. The participants consisted of 27 men and 
19 women, and 12 subjects (26%) were diagnosed with MetS. 
  Abdominal circumference (P<0.001), body mass index (P=
0.023), the concentration of fasting blood glucose (P<0.001), 
triglycerides (P<0.001), and midnight salivary cortisol were 
significantly higher (P=0.001), and the concentration of HDL-
C was lower in subjects with MetS (P=0.001) than those with-
out MetS. Serum insulin concentrations were higher in subjects 
with MetS (P=0.046), and subjects with MetS were more insulin 
resistant than subjects without MetS based on the HOMA-IR.
Partial correlation analysis between midnight salivary 
cortisol, HOMA-IR, and individual MetS components 
Midnight salivary cortisol concentrations were significantly 
and positively correlated with abdominal circumference (r=
0.21, P=0.001), fasting blood glucose (r=0.21, P=0.001), and 
HOMA-IR (r=0.17, P=0.013), but not with blood pressure, 
triglycerides, or HDL-C (Table 2). The correlation between 
midnight salivary cortisol and fasting blood glucose was posi-
tive after excepting two patients with diabetes (r=0.21, P=
0.012).
Table 1. General characteristics of the study subjects
Variable Total (n=46) MetS (+) (n=12) MetS (-) (n=34) P value vs. MetS (-)
Age, yr 40.0 (34.0-82.0)  47.5 (39.3-54.8) 38 (34.0-52.0) 0.122
Sex, M/F 27/19  7/5 20/14 0.271
Diabetes 2 (4.3) 1 (8.3) 1 (2.9) 0.458
AC, cm 87.3 (79.6-92.4) 92.2 (91.3-93.4) 84.2 (76.2-89.5) 0.001
BMI, kg/m
2 24.3 (22.4-26.6) 26.2 (24.1-27.6) 23.5 (21.7-26.1) 0.023
SBP, mm Hg 121 (114.0-133.0) 132 (124.3-137.8) 118 (111-128) 0.375
DBP, mm Hg 80.0 (73.0-89.0) 87.5 (85.3-92.5) 78.0 (71-86) 0.321
TG, mg/dL 110.0 (84.0-154) 219.0 (184.8-290.5) 98.0 (75.0-118.0) <0.001
HDL-C, mg/dL 54.0 (45.0-66.0) 45.5 (39.0-49.5) 58.0 (49.0-70.0) 0.001
FBG, mg/dL 86.0 (80.0-97.0) 99.5 (92.5-115.8) 83.0 (78.0-90.0) <0.001
Insulin, mg/mL 4.7 (2.1-7.5) 7.5 (5.0-8.0) 4.3 (2.0-5.8)  0.046
HOMA-IR 1.40 (1.1-1.72) 2.73 (2.21-3.10)  0.95 (0.82- 1.10) 0.048
hs-CRP, mg/dL 0.11 (0.08-0.12) 0.15 (0.10-0.19)  0.09 (0.07-0.11) 0.232
Midnight salivary cortisol, ng/dL 34.0 (17.0-52.0) 82 .0 (57.8-123.8) 28.0 (14.0-41.7) 0.001
Values are presented as median (interquartile range) or number (%). 
Continuous variables were compared using the Mann-Whitney U test, and categorical variables were compared with the chi-square test.
MetS, metabolic syndrome; AC, abdominal circumference; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
TG, triglyceride; HDL-C, high density lipoprotein cholesterol; FBG, fasting blood glucose; HOMA-IR, homeostasis model assessment-insulin 
resistance; hs-CRP, high-sensitivity C-reactive protein. 
Table 2. Correlations between midnight salivary cortisol and 
components of metabolic syndrome, HOMA-IR, or hs-CRP 
Variable
Midnight salivary cortisol
r
a P value
Age, yr (n=46) 0.14 0.121
AC, cm (n=46) 0.21 0.001
SBP, mm Hg (n=46) 0.11 0.692
DBP, mm Hg (n=46) -0.02 0.891
TG, mg/dL (n=46) 0.12 0.081
HDL-C, mg/dL (n=46) -0.04 0.092
FBG, mg/dL (n=46) 0.21 0.001
HOMA-IR (n=39) 0.17 0.013
hs-CRP, mg/dL (n=38) 0.09 0.092
HOMA-IR, homeostasis model assessment-insulin resistance; hs-
CRP, high sensitivity C-reactive protein; AC, abdominal circumfer-
ence; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, 
triglyceride; HDL-C, high density lipoprotein cholesterol; FBG, fast-
ing blood glucose.
aPartial correlation coefficient adjusted for age and gender. 248
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Logistic regression analysis between midnight salivary 
cortisol levels and MetS
A univariate regression analysis revealed that high midnight 
salivary cortisol concentrations (100 to 150 ng/dL) were relat-
ed to increased odds for MetS (odds ratio [OR], 6.0; 95% con-
fidence interval [CI], 1.8 to 44.3; P=0.001) compared to low 
midnight salivary cortisol concentrations (<50 ng/dL) (Table 
3). This finding remained significant in the multivariate analy-
sis after adjusting for abdominal obesity and impaired fasting 
glucose (OR, 5.9; 95% CI, 2.35 to 36.4). 
DISCUSSION
We have shown that individuals with MetS had two-fold high-
er midnight salivary cortisol concentrations than those with-
out MetS. Midnight salivary cortisol concentrations were posi-
tively correlated with abdominal circumference, fasting blood 
glucose, and HOMA-IR. Furthermore, increased midnight 
salivary cortisol levels were associated with an increased OR 
for MetS. The increased risk was independent of abdominal 
obesity. 
  These observations are consistent with the hypothesis that 
excess production of cortisol might be involved in MetS patho-
genesis. These results agree with those of previous studies that 
found that circulating cortisol concentrations were higher in 
subjects with MetS compared to healthy subjects [16-18].
  Several bodies of evidence suggest that hypercortisolism is 
associated with individual components of MetS. Ward et al. 
[19] found that a higher fasting plasma cortisol level was asso-
ciated with abdominal circumference, triglycerides, and insu-
lin resistance. Philips et al. [20] reported an association between 
fasting plasma cortisol level and blood pressure, fasting glucose 
level, and insulin resistance. Plasma cortisol is less sensitive to 
the HPA axis than salivary cortisol. Nevertheless, most previ-
ous studies have used plasma cortisol levels to evaluate the re-
lationship between hypercortisolism and MetS [21]. The results 
of this study are meaningful in that we used salivary cortisol 
level, which is a more sensitive index of endogenous cortisol 
status and biological activity, to demonstrate the relationship 
between MetS and hypercortisolism. 
  We did not find a significant association between midnight 
salivary cortisol level and blood pressure, which was previous-
ly observed by Kidambi et al. [22]. The reason for this discrep-
ancy is unclear, but there are a few possible explanations. First, 
the number of participants enrolled in our study was small. 
Second, because several participants (n=7, 15.2%) were taking 
antihypertensive drugs, there may not have been a statistical 
difference in blood pressure between subjects with and with-
out MetS. 
  Hypercortisolism may contribute to MetS pathophysiology 
through various mechanisms. First, cortisol promotes differ-
entiation and proliferation of human adipocytes, and cortisol 
receptors are more abundant in viscera adipose tissue than 
that in subcutaneous adipose tissue [23]. Cortisol also redis-
tributes adiposity from peripheral to central depots, and in-
creases the size and number of adipocytes [24]. Consequently, 
excess cortisol causes abdominal obesity, which is an essential 
component of MetS. 
  Second, higher cortisol levels increase blood glucose levels. 
In patients with MetS, serum cortisol levels are significantly 
associated with fasting blood glucose levels [16-18,25]. The ef-
fects of cortisol oppose those of insulin. As a result, cortisol 
induces a state of insulin resistance, leading to diminished sup-
pression of glucose production and reduced peripheral glucose 
uptake [26]. Additionally, cortisol may reduce glucose delivery 
to some tissues by impairing local blood flow [27]. Cortisol also 
suppresses insulin secretion and basal pulsatility [28,29]. As a 
result, cortisol increases blood glucose and the development of 
glucose intolerance and diabetes mellitus. 
  Higher cortisol levels are also associated with hypertension. 
A possible mechanism by which cortisol elevates blood pres-
sure seems to be an increased responsiveness to vasoconstric-
Table 3. Logistic regression to predict metabolic syndrome
Variable OR 95% CI P value
Unadjusted model
Midnight salivary cortisol, ng/dL
<50 (n=30) 1
50≤, <100 (n=9) 1.5 0.3-7.4 0.27
≥100 (n=7) 6.0 1.8-44.3 0.001
Adjusted model
Midnight salivary cortisol, ng/dL
<50 (n=30) 1 0.045
50≤, <100 (n=9) 1.7 0.6-33.2 0.451
≥100 (n=7) 5.9 2.35-36.4 0.013
Abdominal obesity 1.34 0.7-11.5 0.812
IFG (glucose ≥100)  6.6 1.1-26.5 0.047
OR, odds ratio; CI, confidence interval; IFG, impaired fasting glu-
cose.249
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tors along with decreased vasodilator production, as some 
studies have shown that reduced nitric oxide production or 
bioavailability contributes to cortisol-induced hypertension 
[30]. In addition, the endothelin system is activated in patients 
with Cushing’s syndrome, leading to elevated plasma endothe-
lin-1 levels, which probably play a role in the pathogenesis of 
hypertension and early atherosclerosis [30].
  Recently, DeSantis et al. [31] published a study on the asso-
ciation between salivary cortisol levels and MetS and its com-
ponents. The study used data from the Multi-Ethnic Study of 
Atherosclerosis (MESA). It showed that the presence of MetS 
was not associated with cortisol parameters among healthy 
adults. There are some differences between the MESA study 
and ours and there are a few possible explanations for this dis-
crepancy with our study. First, the MESA study participants 
were selected for the absence of clinical cardiovascular disease 
and diabetic patients. Therefore, the proportion of participants 
with adverse metabolic conditions was smaller than in our 
study. Second, the specific cortisol parameter we used differed 
from that of the MESA study. We examined salivary cortisol 
only at midnight, and the MESA study measured cortisol pat-
terns throughout the day.
  Our study has several limitations. First, the number of par-
ticipants enrolled in our study was small. Second, as our study 
was cross-sectional, the results could have limitations with re-
gard to identifying causal relationships. 
  However, our results are meaningful in that this was the 
first study in Korean adults to evaluate the association of mid-
night salivary cortisol with MetS, and we showed that midnight 
salivary cortisol was higher in subjects with MetS than those 
without MetS. We also showed a positive correlation between 
midnight salivary cortisol level and several MetS components. 
These results support the hypothesis that MetS is associated 
with hypercortisolism.
  Further research is needed to confirm a causal relationship 
between higher midnight salivary cortisol levels and MetS. 
Manipulations that reduce cortisol action may have a role in 
the treatment of MetS. 
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